2024-11-09 - Analysis Report
## Vertex Pharmaceuticals Inc (VRTX) Stock Analysis

**1) Performance Comparison:**

Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company focused on developing and commercializing therapies for severe and life-threatening genetic diseases.

VRTX has significantly outperformed the S&P 500 (VOO) over the period analyzed. While VOO has generated a cumulative return of 141.71%, VRTX has delivered a return of 189.87%, leading to a current outperformance of 48.16 points. This translates to a 79.54% relative outperformance, suggesting that VRTX has been in the top 90% of its historical performance range compared to the S&P 500.

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|---|---|---|---|---|
| 2015-2017 | 21.8% | 40.8% | -8.4% | 1.6 |
| 2016-2018 | 34.8% | 35.1% | 10.2% | 1.5 |
| 2017-2019 | 192.4% | 19.3% | 149.3% | 1.2 |
| 2018-2020 | 54.6% | 30.3% | 15.5% | 0.9 |
| 2019-2021 | 33.8% | 37.4% | -56.0% | 0.8 |
| 2020-2022 | 31.6% | 37.4% | 13.9% | 0.7 |
| 2021-2023 | 77.3% | 23.4% | 48.5% | 0.6 |
| 2022-2024 | 125.8% | 17.2% | 101.2% | 0.6 |

The analysis shows VRTX has consistently outperformed the market (Alpha > 0) over the past few years, with a declining beta indicating lower market sensitivity in recent periods.

**2) Recent Price Movement:**

* Closing Price: 502.45
* Last Market: 517.32 (A recent jump in price compared to the closing price)
* 5-day Moving Average: 487.98
* 20-day Moving Average: 481.51
* 60-day Moving Average: 476.19

The stock price is currently above all three moving averages, indicating an upward trend, further supported by the recent jump in price.

**3) Technical Indicators:**

* RSI: 61.83 (above 50, indicating an overbought condition)
* PPO: 0.53 (above 0, indicating bullish momentum)
* Delta_Previous_Relative_Divergence: 3.99 (+), indicating a short-term upward trend.
* Expected Return: 5.9%. This suggests a potential long-term (2+ years) outperformance over S&P 500 through a buy-and-hold strategy.

**4) Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-11-05 | 4.05 | 2.77 B$ |
| 2024-08-02 | -13.92 | 2.65 B$ |
| 2024-05-07 | 4.26 | 2.69 B$ |
| 2023-11-07 | 4.01 | 2.48 B$ |
| 2024-11-05 | 4.01 | 2.48 B$ |

Most recent earnings (2024-11-05) showed a strong beat over analyst expectations. The company continues to show steady revenue growth with increased profitability.

**5) Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30  | $2.77B | 85.84% |
| 2024-06-30  | $2.65B | 85.94% |
| 2024-03-31  | $2.69B | 87.27% |
| 2023-12-31  | $2.52B | 85.38% |
| 2023-09-30  | $2.48B | 87.17% |

VRTX shows consistent revenue growth and consistently high profit margins, reflecting strong market position and profitability. 

**2) Capital and Profitability:**

| Quarter  | Equity     | ROE |
|---|---|---|
| 2024-09-30 | $15.63B   | 6.69% |
| 2024-06-30 | $14.77B | -24.32% |
| 2024-03-31 | $18.55B   | 5.93% |
| 2023-12-31 | $17.58B   | 5.51% |
| 2023-09-30 | $16.51B   | 6.27% | 

ROE shows fluctuations, potentially due to the company’s focus on innovation and growth, which may involve significant investments. 

**6) News and Recent Issues:**

* **Earnings Release:** VRTX recently reported strong Q3 2024 earnings exceeding analysts' expectations, leading to a positive market reaction and a price jump.

**Recent Market Outlook for VRTX:**

* **Finbold** reports a strong bullish sentiment towards VRTX with analysts predicting continued growth fueled by its strong product pipeline and market dominance. 

**Analyst Opinions and Performance Highlights:**

* Analysts generally agree that VRTX is a strong buy, citing its strong product portfolio, growing market share, and pipeline of new drug candidates. 

**7) Comprehensive Analysis:**

VRTX exhibits several positive indicators: consistent outperformance against the S&P 500, strong recent earnings, and a robust product pipeline driving growth.  While RSI suggests an overbought condition, the recent price jump, positive technical indicators, and strong financial metrics continue to support a bullish outlook. 

**8) Summary:**

VRTX is a strong contender for long-term investors seeking growth opportunities within the biotechnology sector. The company's solid financial performance, promising product pipeline, and strong market position suggest continued growth potential and potential for outperforming the market. 

However, it’s crucial to acknowledge the potential risks associated with the biotech industry, including regulatory hurdles, clinical trial setbacks, and competitive pressures. It is recommended to conduct thorough due diligence before investing.
